CGRP Monoclonal Antibody use for the Preventive Treatment of Refractory Headache Disorders in Adolescents.

Monoclonal antibodies (mAbs) to calcitonin gene-related peptide (CGRP) or its receptor have clinical trial evidence in adults with headache, but data are lacking in adolescents.

Source: Pediatric Neurology - October 4, 2020 Category: Neurology Authors: Kaitlin A. Greene, Carlyn Patterson Gentile, Christina L. Szperka, Marcy Yonker, Amy A. Gelfand, Barbara Grimes, Samantha L. Irwin Tags: Research Paper Source Type: research